All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub

Brought to you by Scientific Education Support

Scientific Education Support

The Lupus Hub is an independent medical education platform, sponsored by Autolus, Biogen and Biogen MA, Inc. and UCB. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My Lupus Hub

Create an account to access:

Bookmark & personalize site content

Receive alerts for new content in your areas of interest

View lupus content recommended for you

APLAR Congress 2022

Share:

Dec 7, 2022

X post image

10 Dec 2022

We covered #APLAR22 virtually!

We hope you enjoyed following our live updates and congress coverage.

Keep an eye on our socials for post-congress key points and insights.

#medicalcongress #psoriasis #rheumatology

X post image

9 Dec 2022

CONGRESS #APLAR22 | Mitsumasa Kishimoto discussed the difficulties of differentiating axSpA & axPsA then discussed results from the ASAS-perSpA study which found older age, peripheral arthritis, dactylitis & #psoriasis predictive of axPsA. #psoriaticarthritis

X post image

9 Dec 2022

CONGRESS #APLAR22 | Thaschawee Arkachaisri presented consensus recommendations (recs) in juvenile #SLE: SLICC classification criteria & SHARE initiative 2017 recs for SLE & #lupus nephritis were highlighted for cSLE. Lack of Asia-Pacific recs & challenges in LMICs highlighted.

X post image

9 Dec 2022

CONGRESS #APLAR22 | Christine Bernal @UST1611official shared aspects of managing #lupus in developing LI/MI countries. Managing infections & active #SLE, treating class 3/4N in absence of renal biopsy, using cyclophosphamide vs MMF, cheap/free alternative treatment can be helpful

X post image

9 Dec 2022

CONGRESS #APLAR22 | Sheng-Xiao Zhang @ Shanxi Medical University discussed the association b/w circulating regulatory T cells & pregnancy outcomes in pts with #SLE. Decreased number of Treg cells & imbalanced Treg ratio were associated with adverse pregnancy outcomes #lupus

X post image

9 Dec 2022

CONGRESS #APLAR22 | Mikhail Kostic @ Saint Petersburg State Pediatric Medical University discussed the role of gene in #SLE. >50% of pts with SLE have rare gene variants. Majority of variants coding nucleic acid sensing & IFN-signaling. Mutation in PTPN22 & TREX1:Yakut pts #lupus

X post image

9 Dec 2022

CONGRESS #APLAR22 | Mikhail Kostic @ Saint Petersburg State Pediatric Medical University presented the preliminary data of a retrospective cohort study of rituximab in pediatric patients with #LupusNephritis. Complete remission: 68%, partial improvement: 20%, CS free: 32% #lupus

X post image

8 Dec 2022

CONGRESS #APLAR22 | George Schett
@UniFAU presented results of anti-CD19 #CART cell therapy in 5pts with #SLE. B-cell depletion was successful, and SLEDAI-2K & anti-ds Abs reduced after therapy. Pt1 in remission at 600 days. #lupus See our hub article: https://t.co/Mpjz4zhY23

X post image

8 Dec 2022

CONGRESS #APLAR22 | Thomas SY Chan @ @hkumed discussed the clinical aspect of stem cell transplant in rheumatic disease. Auto-HSCT can be a curative strategy in some rheumatological diseases. Novel treatments are being developed to reduce TRM & preserve the efficacy #lupus

X post image

8 Dec 2022

CONGRESS #APLAR22 | @sarfarazhasni @NIH discussed the current recommendations for the use of glucocorticoids in vasculitides & #SLE. Understanding GCs mechanism, targeted therapies, early immunosuppression, selecting SEGRAM & increase HCQ use can be helpful strategies #lupus

X post image

8 Dec 2022

CONGRESS #APLAR22 | @DandaDebashish @OffCMCVellore discussed the efficacy and safety of deflazacort vs conventional glucocorticoids in #rheumatology practice. Deflazacort was found to have similar efficacy and fewer adverse events compared to prednisolone #lupus

X post image

8 Dec 2022

CONGRESS #APLAR22 | Lin Xie at Shanxi Medical University discussed shared genes & possible therapeutic targets between #SLE & #COVID-19. CDK was commonly associated with progression in both SLE & COVID-19 that can be targeted for the treatment of pts with COVID-19 & SLE #lupus

X post image

8 Dec 2022

CONGRESS #APLAR22 | Ranran Yao @PKU1898 reports the role of MerTK inhibition on NETs formation in #SLE. Increased MerTK expression in the neutrophils of pts with SLE was well correlated with clinical indicators and MerTK inhibition promoted NETs formation in neutrophils #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | T M Chan @ University of Hong Kong discussed the role of kidney biopsy & treatment selection in #lupusnephritis. Understanding pathological features, CNI nephrotoxicity, immunosuppressants tampering, d/s mechanism, & efficacy of novel therapies is vital #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | Chi Chiu Mok at Tuen Mun Hospital reports on advances in #SLE therapies & Asian perspective. Ethnic & non-ethnic factors (genetic, drug properties, disease severity, biomarkers, comorbidity, autoantibody profile) affect treatment response & prognosis #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | Chi Chiu Mok at Tuen Mun Hospital reports on advances in #SLE therapies & Asian perspective. Ethnic & non-ethnic factors (genetic, drug properties, disease severity, biomarkers, comorbidity, autoantibody profile) affect treatment response & prognosis #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | @ChaimPutterman @ubarilan/@EinsteinMed discussed the quest for biomarkers in #SLE. He talked about how the current paradigm of disease management bears the potential risk of overdiagnosis and overtreatment in patients with #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | Sandra Navarra @UST1611official summarized belimumab trials: highlighting the importance of BLyS in #SLE, trial learnings on the use of robust outcomes (SRI) & stringent patient selection, newer indications, & sustained efficacy with no new safety signs #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | @EricFMorand @MonashUniversity presented measurement challenges in #SLE clinical trials in the last 20 years. There are issues in trial design and endpoint that can be solved by formal scientific methodology, patient involvement & regulatory engagement. #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 |@AishwaryaGopal @JIPMER discussed the withdrawal of maintenance glucocorticoids (GC) vs other immunosuppressants (IS) in pts with #SLE. N=117, SFI flares: 25.9 % vs 13.6% (GC vs IS). Results suggested that IS can be a viable option for patients with SLE #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | Qin-Yi Su at the Second Hospital of Shanxi Medical University presented the efficacy and safety results of low-dose IL-2 in patients with #SLE. N=54; SRI-4 response was 81.6% and no SAE was reported. #lupus

X post image

7 Dec 2022

CONGRESS #APLAR22 | Sandra Navarra @UST1611official presented post hoc analysis results from a phase 3 AURORA 2 trial of valcosporin in Asian pts with #lupusnephritis. N=60, UPCR: ≤0.5 mg/mg in a median time of 6.3 months (p=0.001), no new safety events reported. #lupus

X post image

6 Dec 2022

#APLAR22 starts today!

The Lupus Hub is covering APLAR virtually.

Keep an eye on our Twitter page for live updates, key insights, and interview coverage.

#medicalcongress #psoriasis #rheumatology

X post image

6 Dec 2022

#APLAR22 starts today!

The Lupus Hub is covering APLAR virtually.

Keep an eye on our Twitter page for live updates, key insights, and interview coverage.

#medicalcongress #psoriasis #rheumatology

<span> </span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

APLAR 2022 Asia Pacific League of Associations for Rheumatology

Newsletter

Subscribe to get the best content delivered to your inbox